Combination Treatment Strategies to Overcome PARP Inhibitor Resistance

Abstract excerpt

Poly(ADP-ribose) polymerase (PARP) enzymes have been shown to be essential for DNA repair pathways, including homologous recombination repair (HRR). Cancers with HRR defects (e.g., BRCA1 and BRCA2 mutations) are targets for PARP inhibitors (PARPis) based on the exploitation of "synthetic lethality". As a result, PARPis offer a promising treatment option for advanced ovarian and breast cancers with deficiencies in...

Topics

Join the communities discussing this publication.

• DNA Repair Mechanisms
• PARP inhibition in cancer therapy
• Toxin Mechanisms and Immunotoxins